Location via proxy:   [ UP ]  
[Report a bug]   [Manage cookies]                

UNLIMITED

STAT

Opinion: Two words to help Ned Sharpless revolutionize clinical trials: data standards

"Data standards" may not sound as cool as "precision medicine." But they hold the key to making faster, cheaper clinical trials that provide better insights into drug discovery and testing.
Ned Sharpless

In the classic 1967 film “The Graduate,” young Benjamin Braddock was given one word of advice for his future: plastics. In that spirit, I’d like to offer Dr. Ned Sharpless, the new acting commissioner of the Food and Drug Administration, two words of advice for the future of the FDA: data standards.

Like many other experts, I grow increasingly alarmed by the slow progress in the development, implementation, and acceptance of data standards for clinical trials. As the clock ticks, the capital costs and the human costs of inaction are mounting. No matter where my work takes me, I always return to the urgent need for data standards.

I know that

You’re reading a preview, subscribe to read more.

More from STAT

STAT2 min read
STAT+: Pharmalittle: We’re Reading About A Merck Deal, GSK Cancer Drug Data, And More
In a move to safeguard its dominant position in cancer treatments, Merck agreed to license a drug from a Chinese company
STAT2 min read
STAT+: Pharmalittle: We’re Reading About RFK Jr. And Vaccines, Obesity-drug Prescribing For Kids, And More
Robert F. Kennedy Jr. would have broad power as HHS secretary to strip vaccine makers' protections against lawsuits
STAT2 min read
STAT+: Pharmalittle: We’re Reading About GSK Leaving BIO, An AbbVie Schizophrenia Drug Failing, And More
GSK plans to depart the biotechnology industry’s largest trade group, the Biotechnology Innovation Organization

Related Books & Audiobooks